Modalis Therapeutics Corporation (TYO:4883)
Japan
· Delayed Price · Currency is JPY 56.00
-3.00 (-5.08%)
Mar 9, 2026, 3:30 PM JST
Modalis Therapeutics Company Description
Modalis Therapeutics Corporation engages in the research and development of therapeutics to treat patients with serious genetic disorders.
The company is developing therapies for genetic diseases using its proprietary CRISPR-GNDM technology developed by Modalis that combines dCas9.
It also develops various therapeutics for muscle disorders, cardiomyopathy, and CNS disorders. The company was formerly known as EdiGENE Corporation and changed its name to Modalis Therapeutics Corporation in August 2019.
Modalis Therapeutics Corporation was incorporated in 2016 and is headquartered in Chuo, Japan.
Modalis Therapeutics Corporation
| Country | Japan |
| Founded | 2016 |
| Industry | Drug Manufacturers - Specialty & Generic |
| Sector | Healthcare |
| Employees | 14 |
| CEO | Haruhiko Morita |
Contact Details
Address: Nihonbashi-Lifescience-Bldg.2 Chuo, 103-0023 Japan | |
| Website | modalistx.com |
Stock Details
| Ticker Symbol | 4883 |
| Exchange | Tokyo Stock Exchange |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | JPY |
| ISIN Number | JP3922600006 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Haruhiko Morita | Chief Executive Officer |